The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
The facility is expected to be completed in 2024
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
As of 2nd May 2021, the Government has provided more 16.54 crore COVID-19 vaccine doses to States/UTs free of cost
Subscribe To Our Newsletter & Stay Updated
